Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis

Next Previous
X
Search
Trial Profile

A Phase 2, Randomized, Placebo-controlled, Double-blind, Multiple Dose Study to Evaluate the Efficacy and Safety of ANB019 in Subjects With Palmoplantar Pustulosis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jun 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imsidolimab (Primary)
  • Indications Palmoplantar pustulosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms POPLAR
  • Sponsors AnaptysBio

    • Most Recent Events

    • 05 May 2022 Status changed from discontinued to completed.
    • 13 May 2021 This trial has been completed in Germany (End Date: 23 Apr 2021), according to European Clinical Trials Database record.
    • 08 Mar 2021 According to an Anaptys Bio media release, does not currently plan to conduct further clinical development of imsidolimab in PPP

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top